To date, the data we have on BC and PD-1/PD-L1-based therapies are promising: activity has been shown for all the mentioned antibodies, even though the overall response rate was found to be highly variable; this is probably also due to the lack of a standardized method to select the BC cohorts that can benefit from these therapies [148]. Here, CD274 is linked to breast cancer.